Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AMPHNASDAQ:AURANASDAQ:CALTNASDAQ:OCUL On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAMPHAmphastar Pharmaceuticals$24.43+2.3%$25.96$22.64▼$53.96$1.13B0.78471,467 shs819,839 shsAURAAura Biosciences$4.94-9.7%$6.19$4.84▼$12.38$248.21M0.43203,088 shs210,822 shsCALTCalliditas Therapeutics AB (publ)$40.00$40.00$15.25▼$43.00$1.19B1.7710,339 shsN/AOCULOcular Therapeutix$7.05-1.8%$7.42$4.79▼$11.78$1.14B1.511.42 million shs1.99 million shsFree Today: Your Guide to Smarter Options TradesLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAMPHAmphastar Pharmaceuticals+2.43%+0.08%-2.28%-25.50%-42.88%AURAAura Biosciences-9.83%-15.23%-10.47%-38.30%-34.02%CALTCalliditas Therapeutics AB (publ)0.00%0.00%0.00%0.00%+93.80%OCULOcular Therapeutix-1.81%-15.06%+11.90%-7.72%+18.89%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAMPHAmphastar Pharmaceuticals4.5062 of 5 stars3.03.00.03.73.84.21.3AURAAura Biosciences2.2983 of 5 stars3.62.00.00.02.82.50.0CALTCalliditas Therapeutics AB (publ)N/AN/AN/AN/AN/AN/AN/AN/AOCULOcular Therapeutix3.3762 of 5 stars3.41.00.04.12.41.70.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAMPHAmphastar Pharmaceuticals 2.00Hold$43.5078.06% UpsideAURAAura Biosciences 3.25Buy$22.75360.34% UpsideCALTCalliditas Therapeutics AB (publ) 2.00Hold$39.25-1.88% DownsideOCULOcular Therapeutix 2.88Moderate Buy$16.25130.50% UpsideCurrent Analyst Ratings BreakdownLatest AURA, OCUL, AMPH, and CALT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/6/2025OCULOcular TherapeutixNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$15.00 ➝ $14.004/10/2025AMPHAmphastar PharmaceuticalsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingHold ➝ Hold4/8/2025OCULOcular TherapeutixWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform4/8/2025OCULOcular TherapeutixNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$15.00 ➝ $15.003/26/2025AURAAura BiosciencesJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price Target$19.003/26/2025AURAAura BiosciencesCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform3/25/2025AURAAura BiosciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price Target$25.003/24/2025AURAAura BiosciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$22.00 ➝ $22.003/21/2025AMPHAmphastar PharmaceuticalsPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$36.00 ➝ $32.003/18/2025OCULOcular TherapeutixRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$17.003/11/2025OCULOcular TherapeutixNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$15.00(Data available from 5/8/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAMPHAmphastar Pharmaceuticals$731.97M1.59$3.41 per share7.17$13.35 per share1.83AURAAura BiosciencesN/AN/AN/AN/A$4.58 per shareN/ACALTCalliditas Therapeutics AB (publ)$1.60B0.74N/AN/A$1.06 per share37.74OCULOcular Therapeutix$59.65M18.83N/AN/A$0.79 per share8.92Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAMPHAmphastar Pharmaceuticals$137.54M$3.068.147.432.1921.80%26.44%11.89%N/AAURAAura Biosciences-$76.41M-$1.75N/AN/AN/AN/A-41.57%-36.43%5/8/2025 (Estimated)CALTCalliditas Therapeutics AB (publ)-$43.96M-$1.85N/A8.68N/A-30.18%-212.04%-27.96%N/AOCULOcular Therapeutix-$80.74M-$1.15N/AN/AN/A-283.74%-45.18%-30.87%N/ALatest AURA, OCUL, AMPH, and CALT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/8/2025Q1 2025AURAAura Biosciences-$0.45N/AN/AN/AN/AN/A3/24/2025Q4 2024AURAAura Biosciences-$0.43-$0.52-$0.09-$0.52N/AN/A3/3/2025Q4 2024OCULOcular Therapeutix-$0.24-$0.29-$0.05-$0.29$16.89 million$17.08 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAMPHAmphastar PharmaceuticalsN/AN/AN/AN/AN/AAURAAura BiosciencesN/AN/AN/AN/AN/ACALTCalliditas Therapeutics AB (publ)N/AN/AN/AN/AN/AOCULOcular TherapeutixN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAMPHAmphastar Pharmaceuticals0.823.432.61AURAAura BiosciencesN/A12.4712.47CALTCalliditas Therapeutics AB (publ)9.442.692.59OCULOcular Therapeutix0.1913.0112.94Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAMPHAmphastar Pharmaceuticals65.09%AURAAura Biosciences96.75%CALTCalliditas Therapeutics AB (publ)2.83%OCULOcular Therapeutix59.21%Insider OwnershipCompanyInsider OwnershipAMPHAmphastar Pharmaceuticals27.50%AURAAura Biosciences5.40%CALTCalliditas Therapeutics AB (publ)2.20%OCULOcular Therapeutix3.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAMPHAmphastar Pharmaceuticals1,62047.50 million35.05 millionOptionableAURAAura Biosciences5050.23 million47.25 millionNot OptionableCALTCalliditas Therapeutics AB (publ)18029.79 million29.14 millionOptionableOCULOcular Therapeutix230159.29 million151.71 millionOptionableAURA, OCUL, AMPH, and CALT HeadlinesRecent News About These CompaniesOcular Therapeutix (NASDAQ:OCUL) Price Target Cut to $14.00 by Analysts at Needham & Company LLCMay 8 at 8:39 AM | marketbeat.com212,944 Shares in Ocular Therapeutix, Inc. (NASDAQ:OCUL) Acquired by First Trust Advisors LPMay 8 at 3:37 AM | marketbeat.comOcular Therapeutix (NASDAQ:OCUL) Stock Price Down 6.5% Following Analyst DowngradeMay 8 at 1:43 AM | americanbankingnews.comOcular Therapeutix (NASDAQ:OCUL) Shares Gap Down - What's Next?May 7 at 12:27 PM | marketbeat.comVIDEO: OTX-TKI reduces intraretinal fluid over 1 year with single injectionMay 7 at 11:33 AM | healio.comAnalysts Just Slashed Their Ocular Therapeutix, Inc. (NASDAQ:OCUL) EPS NumbersMay 7 at 11:33 AM | finance.yahoo.comOcular Therapeutix (NASDAQ:OCUL) Announces Quarterly Earnings ResultsMay 7 at 8:12 AM | marketbeat.comAptus Capital Advisors LLC Has $2.90 Million Stock Holdings in Ocular Therapeutix, Inc. (NASDAQ:OCUL)May 7 at 5:14 AM | marketbeat.comPrice T Rowe Associates Inc. MD Has $5.46 Million Stock Position in Ocular Therapeutix, Inc. (NASDAQ:OCUL)May 7 at 4:08 AM | marketbeat.comOcular Therapeutix First Quarter 2025 Earnings: Misses ExpectationsMay 6 at 8:54 AM | finance.yahoo.com1OCUL : Analyst Expectations For Ocular Therapeutix's FutureMay 6 at 8:54 AM | benzinga.comWhy Ocular Therapeutix, Inc.’s (OCUL) Stock Is Down 9.09%May 5 at 9:07 PM | aaii.comOcular Therapeutix Stock Falls as 1Q Misses Targets, R&D Expenses DoubleMay 5 at 4:05 PM | marketwatch.comOcular Therapeutix stock tumbles as Q1 results miss estimatesMay 5 at 11:04 AM | au.investing.comOcular Therapeutix™ Reports First Quarter 2025 Results and Business HighlightsMay 5 at 11:04 AM | finance.yahoo.comOcular Therapeutix (OCUL) Reports Q1 Loss, Misses Revenue EstimatesMay 5 at 9:15 AM | zacks.comVoya Investment Management LLC Has $3.17 Million Stock Holdings in Ocular Therapeutix, Inc. (NASDAQ:OCUL)May 5 at 4:23 AM | marketbeat.comWells Fargo & Company MN Has $634,000 Position in Ocular Therapeutix, Inc. (NASDAQ:OCUL)May 5 at 3:15 AM | marketbeat.comAcuta Capital Partners LLC Has $9.49 Million Stock Holdings in Ocular Therapeutix, Inc. (NASDAQ:OCUL)May 4, 2025 | marketbeat.comRaymond James Financial Inc. Takes Position in Ocular Therapeutix, Inc. (NASDAQ:OCUL)May 4, 2025 | marketbeat.comOcular Therapeutix Inc (OCUL) Q1 2025: Everything You Need To Know Ahead Of EarningsMay 3, 2025 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesAre Tariffs Threatening Disney’s Comeback Story?By Jea Yu | April 9, 2025View Are Tariffs Threatening Disney’s Comeback Story?Archer Aviation Gets Analyst Target Upgrade: Time to Load Up?By Jeffrey Neal Johnson | April 25, 2025View Archer Aviation Gets Analyst Target Upgrade: Time to Load Up?Why D-Wave's Project With Davidson Is a Game-Changer For QuantumBy Nathan Reiff | April 30, 2025View Why D-Wave's Project With Davidson Is a Game-Changer For Quantum5 Highest-Rated Dividend Stocks According to MarketBeatBy Thomas Hughes | April 10, 2025View 5 Highest-Rated Dividend Stocks According to MarketBeatDave & Buster’s Stock: A Short-Squeeze PLAY for Q2By Thomas Hughes | April 10, 2025View Dave & Buster’s Stock: A Short-Squeeze PLAY for Q2AURA, OCUL, AMPH, and CALT Company DescriptionsAmphastar Pharmaceuticals NASDAQ:AMPH$24.43 +0.56 (+2.35%) Closing price 05/7/2025 04:00 PM EasternExtended Trading$24.48 +0.05 (+0.20%) As of 08:54 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency. The company provides Amphadase, an injection to absorb and disperse other injected drugs; Epinephrine injection for allergic reactions; Lidocaine jelly, an anesthetic product for urological procedures; Lidocaine topical solution for various procedures; Phytonadione injection, a vitamin K1 injection for newborn babies; emergency syringe products; morphine injection for use with patient-controlled analgesia pumps; and Lorazepam injection for surgery and medical procedures. In addition, it offers Neostigmine methylsulfate injection to treat myasthenia gravis and to reverse the effects of muscle relaxants; Isoproterenol hydrochloride injection for mild or transient episodes of heart block; Ganirelix Acetate injection for the inhibition of premature luteinizing hormone surges; Vasopressin to increase blood pressure; and Regadenoson, a stress agent for radionuclide myocardial perfusion imaging. Further, the company distributes recombinant human insulin APIs and porcine insulin API. Additionally, it develops generic product candidates, such as injectable, inhalation, and analytical technologies; biosimial product candidates; and intranasal epinephrine for the treatment of allergic reactions. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.Aura Biosciences NASDAQ:AURA$4.94 -0.53 (-9.65%) Closing price 05/7/2025 03:59 PM EasternExtended Trading$4.98 +0.04 (+0.77%) As of 04:21 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Aura Biosciences, Inc., a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates. Its lead candidate is bel-sar, which is in late-stage clinical development for the treatment of patients with primary choroidal melanoma and other ocular oncology indications, as well as in early-stage clinical development in bladder cancer. The company also focuses on assessing the safety and efficacy of bel-sar in treating a range of other solid tumors, including bladder cancer as an alternative to bacillus calmetteguérin therapy. Aura Biosciences, Inc. was incorporated in 2009 and is headquartered in Boston, Massachusetts.Calliditas Therapeutics AB (publ) NASDAQ:CALT$40.00 0.00 (0.00%) As of 05/6/2025Calliditas Therapeutics AB (publ), a commercial-stage bio-pharmaceutical company, focused on identifying, developing, and commercializing novel treatments in orphan indications with an initial focus on renal and hepatic diseases with significant unmet medical needs in the United States, Europe, and Asia. It offers Nefecon (TARPEYO/Kinpeygo), an oral formulation of budesonide to reduce the loss of kidney function in adults with immunoglobulin A nephropathy. The company's lead compound is Setanaxib, a NOX inhibitor that is in Phase 2b clinical trial for the treatment of primary biliary cholangitis; and in Phase 2 clinical trial for the treatment of squamous cell carcinoma of the head and neck cancer and idiopathic pulmonary fibrosis, as well as for solid tumors and Alport Syndrome. Calliditas Therapeutics AB (publ) was incorporated in 2004 and is headquartered in Stockholm, Sweden.Ocular Therapeutix NASDAQ:OCUL$7.05 -0.13 (-1.81%) Closing price 05/7/2025 04:00 PM EasternExtended Trading$7.17 +0.12 (+1.65%) As of 09:10 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is developing AXPAXLI, an axitinib intravitreal implant that is in phase 3 trials for the treatment of wet age-related macular degeneration and other retinal diseases; PAXTRAVA, a travoprost intracameral implant, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension; OTX-CSI, a cyclosporine intracanalicular insert that has completed phase 2 clinical trials for the treatment of dry eye disease; and OTX-DED, a dexamethasone intracanalicular insert, which is in phase 2 clinical trials for the short-term treatment of the signs and symptoms of dry eye disease. In addition, the company offers modulator for intermediate and late dry age-related macular degeneration; and gene delivery for inherited retinal degenerations and protein biofactory indications. The company has a strategic collaboration with Regeneron Pharmaceuticals, Inc. (Regeneron) for the development and commercialization of products using the company's sustained-release hydrogel in combination with Regeneron's large molecule VEGF-targeting compounds for the treatment of retinal diseases; and AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC. Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Disney Stock Jumps on Earnings—Is the Magic Sustainable? AMD Relieves Market Despite Ongoing Share Price Outlook Caution Gold’s Record Run in 2025: Here Are 3 Ways to Ride the Surge Institutions Skipped the Rally: Where the Money Went What the New Quarter Says About Super Micro Computer's Future Archer Stock Eyes Q1 Earnings After UAE Updates Ford Motor Stock Rises After Earnings, But Momentum May Not Last Broadcom Stock Gets a Lift on Hyperscaler Earnings & CapEx Boost Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
